Search

Displaying results 3261 - 3270 of 7540 in total
  1. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  2. Drug

    Montmorillonite

    go.drugbank.com/drugs/DB13654
    Investigational

    Mixtures: SEED Teatree and Lime Vegan No-sebum Cool Anti HairlossShampoo
  3. Drug

    Edrophonium

    go.drugbank.com/drugs/DB01010
    Approved

    It has also been used as an antidote to curare principles.

    Synonyms: 3-hydroxy-N,N-dimethyl-N-ethylanilinium, N-ethyl-3-hydroxy-N,N-dimethylanilinium
  4. Drug

    Thallous chloride

    go.drugbank.com/drugs/DB09316
    ApprovedWithdrawn

    Thallous chloride (also known as Thallium(I) chloride) is a colourless solid intermediate in the isolation of thallium from its ores. It is created from the treatment of thallium(I) sulfate with hydrochloric acid. This solid crystallizes...

  5. Drug

    Flavoxate

    go.drugbank.com/drugs/DB01148
    Approved

    Its therapeutic usefulness and its mechanism of action are not clear. … It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]

  6. Drug

    Cintredekin besudotox

    go.drugbank.com/drugs/DB05305
    Investigational

    Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual … Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, _Pseudomonas exotoxin_ (PE). The IL13 portion binds to receptors on the tumor.

  7. Drug

    Dimetindene

    go.drugbank.com/drugs/DB08801
    ApprovedInvestigational

    Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.

  8. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    [L51733] Due to the amino acid substitutions in the Fc region (M435L/N441A), pemivibart has an extended serum half-life.[L51728]

  9. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    or as an alternative to erythromycin treatment [A176170]. … It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections

  10. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.